hiPS-CMs for the Study of Novel Long-QT Variants
variants in any given individual. 2 Determining which of these is the truly causal genetic variant is thus one of the challenges in the treatment of heritable conditions, especially when the causal gene is of unknown function. Bioinformatic approaches can then be used to prioritize such novel variants, for example, identifying variants (1) that are absent from public databases, (2) in genes previously shown to harbor common variants for a related phenotype, (3) in genes with disease-relevant expression profiles, (4) with strong predicted functional impact, etc. Given that rare and benign variants in the 3 major LQTS genes are expected in 1 in 25 healthy individuals, 3, 4 however, functional validation and confirmatory segregation results are needed as a proof of causality, even if novel genetic variants are found in a known LQTS gene. In the event that no family members are available for genetic analyses, functional validation becomes even more crucial. There is, therefore, a need to develop approaches to rapidly validate the functional impact of potentially causal novel mutations, without the confounding presence of the other novel variants.
Novel causal variants in LQTS have mostly been functionally characterized in heterologous expression systems, such as human embryonic kidney (HEK) cells or isolated cardiomyocytes from animal models. Although these may enable some mechanistic studies, nonexcitable cells cannot be used for the study of electrophysiological features relevant for LQTS. In addition, animal models may not reflect the physiology of cells/tissues that are affected in human disease. Functional studies using human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) derived from patients are an interesting alternative, addressing the physiological limitations. In LQTS, studies have shown that patient-derived hiPSCMs can recapitulate disease phenotypes and can serve to study LQTS pathophysiology, as well as a drug-testing platform. [5] [6] [7] [8] [9] Although hiPS-CMs derived from patients represent a valuable model for functional studies, the interpretation of the results can sometimes be confounded given that the causal mutation is found within a background of hundreds of nonsynonymous coding variants carried by the same individual. 2 Furthermore, obtaining patient-derived hiPS-CMs is a long and costly process, which is not suitable for rapid screening of multiple novel variants.
In the current study, we evaluated the use of a commercially available human derived cardiomyocyte cell line (potentially a small panel in the future), combined with genetic perturbation as a means for screening novel variants in an electrophysiologically relevant context. As a first step, we characterized the transcriptome, channel localization, and electrophysiological properties of hiPS-CMs. In this study, we performed wholeexome sequencing (WES) in a patient with a high probability of LQTS, as reflected by a Schwartz score of 5, 10 but who was found to be negative on clinical genetic testing of the 5 most frequently implicated genes in LQTS (KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2). We identified a putative causal mutation (Gly52Val) in KCNJ2 that encodes the pore-forming α-subunit of the inward-rectifier potassium channel Kir2.1 and that is associated with Andersen-Tawil syndrome (ATS). To date, >70 different mutations in KCNJ2 have been reported in patients with ATS. 11 ATS, a subtype of LQTS (LQTS7), is a rare hereditary multisystem disorder characterized by a range of symptoms that include periodic paralysis, dysmorphic features, and cardiac arrhythmia. Our patient had classical ATS clinical manifestations, such as ECG characteristics containing QTc interval prolongation and presence of abnormal U waves. 12, 13 However, ATS diagnosis is challenging given that clinical manifestations are variable and depend greatly on the position of the variant within the protein structure.
14 We performed basic characterization of the variant in the standard HEK model and then evaluated this mutation, as a proof of principle, in hiPS-CMs to thoroughly assess its effect on electrophysiological parameters. We show here that Kir2.1-52V fails to form functional channels and inhibits endogenous I K1 in hiPS-CMs. In addition, expression of the mutated channel was associated with reduced excitability and prolonged action potential (AP) favoring arrhythmias. We show that commercially available hiPS-CMs can be a powerful isogenic model for screening and functional characterization of newly identified potentially causative variants and genes, without requiring access to patient cells, and thus is complementary to existing tools.
Methods

Proband Recruitment
The subject described in this study, a 37-year-old woman, was recruited at the Cardiovascular Genetics Center of the Montreal Heart Institute. Informed consent was obtained for the subject and her 2 sons according to procedures approved by the Montreal Heart Institute Ethics Review Board.
WES and Validation Genotyping
We used a WES approach to identify the underlying genetic cause for LQTS in the proband. For this, the patient's genomic DNA sample was sequenced on the HiSeq2000 high-throughput sequencing platform (Illumina) according to the manufacturer's protocols.
Cell Culture and Transient Transfections
HEK cells (ATCC) stably expressing the wild-type or the mutant Kir2.1 channel were used for experiment. Detailed protocols are described in the Data Supplement.
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Cor.4U Human iPS Cell-Derived Cardiomyocytes (Axiogenesis AG, Germany) were thawed as described in the manufacturer's protocol and maintained in Cor.4U complete medium. Detailed protocols are described in the Data Supplement. Analyses were conducted between 14 and 21 days post-thaw as specified in figure legends. When applicable, cells were paced using C-PACE EP culture pacer (IonOptix) for 14 days after 7 days in culture (21 days total) at a frequency of 1 Hz using 5 ms pulses at 2.5 to 5 V/cm. Transient transfections in hiPS-CMs were performed using TransIT-LT1 (Mirus Bio) in a 3:1 reagent: DNA ratio with pLVX-IRES-ZsGreen1-Kir2.1-G52, 52V or control empty vector for 48 hours, and electrophysiological experiments were conducted in green fluorescent protein-positive cells.
RNA Isolation and Gene Expression Profiling
For gene expression profiling, total RNA from undifferentiated iPS cells, hiPS-CMs (day 7 and day 14), and cardiac fibroblasts was isolated from >0.3×10 6 cells pellets using an RNeasy micro kit (Qiagen) following the manufacturer's standard protocol. Commercially available RNA was used for total heart and skeletal muscle (Clontech/ Takara). Gene expression was evaluated using a custom Agilent expression array. hiPS-CMs for the Study of Novel Long-QT Variants
Cellular Electrophysiology
Whole-cell voltage-clamp technique was used to record I K1 from HEK and various ionic currents from hiPS-CMs using a patch-clamp amplifier (Axopatch 200B, Molecular Devices, Sunnyvale, CA). All protocols are described in the Data Supplement.
Immunohistochemistry
Immunohistochemistry analyses in HEK cells and hiPS-CMs were done following protocols detailed in the Data Supplement.
Statistical Analysis
Data are expressed as mean and 95% confidence interval, and n values represent independent experiments (different cells from different preparation). Electrophysiological data in Figure 2B and Figures IB and IIC in the Data Supplement were compared using 1-way ANOVA with Tukey procedure on contrasts. Statistical analysis was performed using Origin 8.0 (OriginLab Corporation, MA).
Results
Case Description
Cardiac Manifestations
The patient of French-Canadian descent presented initially at 13 years of age with asymptomatic polymorphic premature ventricular contractions and frequent episodes of nonsustained ventricular tachycardia, which disappeared during exercise. ECG revealed the presence of important ventricular ectopy at rest. Of note, the QTc interval was normal with prominent U waves and prolonged Q-U interval ( Figure 1A ). An echocardiogram revealed no structural cardiac anomalies with a normal left ventricular ejection fraction. At age of 16 years, an electrophysiology study was performed: nonsustained ventricular tachycardia was induced with 2 extra stimuli. A Holter monitor revealed that 50.7% of all recorded heartbeats were ventricular in origin with episodes of bidirectional ventricular tachycardia ( Figure 1B) . The patient received no therapy until 29 years of age when she presented with her first episode of sudden syncope and was admitted for investigation. A cardiac MRI was normal, and electrocardiographic monitoring revealed multiple episodes of asymptomatic nonsustained ventricular tachycardia. β-Blockers were ineffective in suppressing ventricular arrhythmia. Amiodarone was started with the intent to decrease the number of episodes of ventricular tachycardia. One week after amiodarone initiation, she had 4 additional episodes of syncope and was readmitted for investigation. The ECG showed a prolonged QTc of 510 ms while receiving amiodarone, and electrocardiographic monitoring showed sustained polymorphic ventricular tachycardia (Figure 1C) . A dual chamber implantable cardiovertor-defibrillator 2) and her children using polymerase chain reaction product containing the genomic region of the mutation. hiPS-CMs for the Study of Novel Long-QT Variants was implanted, amiodarone was stopped, and β-blockers were reinitiated. For the next 13 years, no recurrent syncope or appropriate shocks occurred. Her implantable cardiovertordefibrillator interrogations revealed occasional nonsustained ventricular tachycardia and numerous episodes of paroxysmal atrial fibrillation. Physical examination revealed dystrophic features, including a hypoplastic chin and short stature. There was no history of muscle weakness.
Family History
The family tree is shown in Figure 1D . The proband's maternal grandfather (I:3) died suddenly at the age of 45 years. Her mother (II:2) presented with syncope at 25 years of age and has had a history of premature ventricular contractions. Further clinical or genetic evaluation was impossible for her. The proband has 3 children, the first (IV:1) died in utero; the second (IV:2) was asymptomatic but presented at age 12 years with premature ventricular contractions, ventricular couplets, a normal QTc interval, and the presence of prominent U waves. This individual was also noted to have short stature and hypoplastic chin. He also had history of intermittent muscle weakness. The third (IV:3) is asymptomatic without any dysmorphic features with a normal ECG. No cardiac phenotype was present in any other family member.
WES Revealed a Mutation in KCNJ2
Overall, our WES identified 43 314 high quality single nucleotide variants and insertions/deletions in the subject. Given the prevalence of LQTS, the fact that LQTS can independently be caused by many different genes, and the fact that most mutations identified to date are nonsynonymous and familial in nature, we opted to focus our analyses exclusively on novel nonsynonymous variants. To achieve this, we filtered-out all previously reported variants from public single-nucleotide polymorphism databases (eg, 1000 Genomes Project, database of short genetic variations, etc), as well as all synonymous variants. After this filtering strategy, we identified 108 novel nonsynonymous coding variants in our subject. A first screen of the 16 known LQTS genes revealed a heterozygous single base pair mutation in the LQTS gene KCNJ2 resulting in a glycine to valine substitution at position 52 (p.Gly52Val). This variant was absent from the genome Aggregation Database (gnomAD) containing >130K WES and whole-genome sequencing data sets. 15 We developed a genotyping assay to independently confirm that the mutation was present in the proband and absent in 540 ethnically matched French-Canadian chromosomes. Analysis of the mutation in the proband's children confirms cosegregation of the variant with the ATS phenotype ( Figure 1D and 1E ). In addition, this variant was predicted as probably damaging based on its pathogenicity score in Polyphen2 (data not shown).
Kir2.1-52V Fails to Form Functional Channel, Is Associated With Loss of I K1 Current, and Has a Dominant-Negative Phenotype in HEK Cell Model
As a primary screen to determine the impact of the Kir2.1-52V variant, characterization studies were conducted in HEK cells that transiently or stably expressed constructs containing empty vector or either wild-type (G52) or mutant (52V) alleles. Using a whole-cell patch-clamp approach, we demonstrated a robust I K1 current in HEK transiently or stably expressing Kir2.1-G52 ( Figure I in the Data Supplement and Figure 2 , respectively). This current presented typical electrophysiological and pharmacological properties of I K1, including a strong inward rectification and high Ba 2+ sensitivity. In contrast, no current could be detected in HEK cells transfected with the empty vector alone or with Kir2.1-52V, suggesting that the Kir2.1-52V mutation results in a nonfunctional ion channel.
Because the patient was heterozygous for the Kir2.1-52V variant, we next looked at the impact of Kir2.1-52V on the wild-type subunit. Our patch-clamp analyses show that coexpression of Kir2.1-G52 with Kir2.1-52V resulted in a dramatic reduction (>80% at −60 mV; P=1.54E-7) of I K1 current density, regardless of whether it is expressed stably or transiently (Figure 2A and 2B). Our data indicate that Kir2.1-52V has a dominant-negative effect that drastically reduces the function of the Kir2.1-G52 channel.
Kir2.1-G52V Mutation Blocks Golgi Export to Plasma Membrane
To determine whether the decreased I K1 current observed in cells expressing Kir2.1-52V was caused by altered surface expression of the Kir2.1, we conducted immunohistochemistry studies in cells overexpressing either the Kir2.1-G52 or Kir2.1-52V channel. We showed that the Kir2.1-G52 channel colocalizes with the membrane-specific wheat germ agglutinin marker ( Figure 2C ). In contrast, the Kir2.1-52V channel showed significant accumulation within the Golgi apparatus as reflected by its colocalization with a member of the transGolgi network peripheral membrane, Golgin97 ( Figure 2D ). Projection of pixel colocalization of fluorescent signals obtained for plasma membrane (wheat germ agglutinin) and Kir2.1 showed that while the wild-type Kir2.1-G52 colocalizes with wheat germ agglutinin, the mutant Kir2.1-52V showed minimal membrane labeling limited to the Golgi area ( Figure 2E ). Together, these results suggest a defect in channel maturation or trafficking caused by Kir2.1-52V.
Characterization of hiPS-CM as a Model to Study Channelopathy-Causing Mutations
To determine whether the Kir2.1-52V mutation impacts electrophysiological parameters implicated in LQTS, we evaluated this variant in Cor.4U hiPS-CMs. We first conducted a characterization study to determine the optimal experimental conditions. We focused our study on gene expression profiling, cellular localization of key ion channels, and electrophysiological phenotyping. Specifically, we conducted gene expression profiling of hiPS-CMs at 7 and 14 days post-thaw compared with that of cardiac fibroblasts and parental hiPS cells, as well as human adult heart and skeletal muscle tissues. As expected, our microarray analysis revealed that hiPS-CMs show absence of signal for stem cells markers (eg, NANOG, POUF5F1), as well as higher expression levels of maturation marker genes (eg, COX6A2, CRYAB) compared with undifferentiated hiPS. Moreover, hiPS-CMs after 7 and 14 days of culture showed an increased expression of major cardiac marker genes, such as cardiac transcription factors (NKX2.5 and GATA4) and structural elements (TNNT2 and MYH7). More interestingly, we also demonstrated that many known LQTS genes, such as KCNQ1, hiPS-CMs for the Study of Novel Long-QT Variants KCNH2, and SCN5A, as well as other ion channels, such as KCNJ4, are expressed in hiPS-CM at 7 and 14 days (Figure 3) .
In terms of immunohistochemistry, we looked at key ion channels localization in hiPS-CMs. Interestingly, despite an increased KCNJ2 gene expression in hiPS-CMs between 7 and 14 days revealed by the microarray analysis, our immunohistochemistry study revealed that at 14 days post-thaw, Kir2.1 channel localizes to the perinuclear region ( Figure 4A ) while Nav1.5 ( Figure 4B ) and CaV1.2 channels are expressed at the plasma membrane ( Figure 4C ).
In terms of electrophysiology, manual patch-clamp technique revealed robust presence of key cardiac ionic currents, including outward K + currents, I Na , and I CaL ( Figure 4D-4F ). In contrast, I K1 current was undetectable in 14 days post-thaw. To induce further maturation, cells were submitted to electric stimulation for 14 days starting at 7 days post-thaw (total of 21 days in culture). Pacing resulted in a robust increase of Kir2.1 plasma membrane expression ( Figure 5A and 5B) concomitant with an increase of a typical cardiac inwardly rectifying I K1 current ( Figure 5C ). In addition, the resting membrane potential (RMP) from 14 day paced cells was decreased to −71.4±2.6 mV, indicating that such stimulation results in a physiologically significant increase in I K1 current associated with hyperpolarization of membrane potential. Altogether, these results emphasize the use of this model for the study of the functional impact of novel variants in inherited channelopathies.
Kir2.1-52V Fails to Form Functional Channels in hiPS-CMs
To demonstrate that hiPS-CMs can be used as a screening model to functionally characterize candidate variants in inherited arrhythmias, we wanted to reproduce the molecular aspect described in HEK cells using Kir2.1-52V variant as a proof of principle. We benefited from the absence of endogenous I K1 current in unpaced hiPS-CMs to directly evaluate our various KCNJ2 constructs. Our immunohistochemistry analysis in transfected hiPS-CMs revealed that Kir2.1-G52 is highly expressed at the plasma membrane ( Figure 6A ) while Kir2.1-52V colocalizes with Golgin97 ( Figure 6B) . Transfection of Kir2.1-G52 into 14-day 
Kir2.1-52V Inhibits Endogenous I K1 and Alters Excitability and AP Configuration in hiPS-CMs
We then wanted to test the impact of Kir2.1-52V on physiologically relevant electrophysiological parameters, such as functional and endogenous I K1 current, excitability, and AP. Transfection of Kir2.1-52V in 14-day paced hiPS-CMs completely abolished the I K1 current induced by electric pacing (Figure 7A and 7B) . Kir2.1-52V also abolished the pacinginduced gain in RMP which reverted from −71.4±1.7 mV (n=17) to −50.3±2.5 mV (n=6). Consistent with a dominantnegative effect and loss of RMP, transfection of Kir2.1-52V in paced hiPS-CMs caused a dramatic decrease in cell excitability. Indeed, the chance of triggering a successful AP in Kir2.1-52V-transfected cells (30%, 3 of 10 cells) was reduced compared with the paced group where 74% of cells (11 of 15 cells) were able to generate an AP with an estimated action potential duration 90 of 364±49 ms. Furthermore, in the Kir2.1-52V-transfected cells that were actually able to generate an AP, AP configurations were variable and triggering required a much higher electric stimulus (>1.5 nA) to overcome the depolarized RMP. Interestingly, beyond lower excitability, among the 3 Kir2.1-52V-transfected cells that were able to generate AP, 1 presented with dramatic AP duration prolongation and 2 had evidence of unpredictable types of arrhythmic activity, such as early-after depolarization and spontaneous activity ( Figure 7C ). Overall, using isogenic hiPS-CMs, we were able to demonstrate the dominant-negative effect of Kir2.1-52V responsible for the ATS clinical manifestation.
Discussion
Clinical sequencing, typically done using the Sanger method, has been the workhorse for diagnostic testing in LQTS for many years. The targeted nature of this testing, with some clinical laboratories routine testing being limited to the 5 genes most commonly mutated in LQTS, leaves upward of 30% of patients without a genetically confirmed diagnosis. 1 Common use of clinical genome and exome sequencing has greatly improved the identification of disease-causing variants. However, considering that some overlapping clinical phenotypes between LQTS and other inherited arrhythmia syndromes exist, such as observed in patients with ATS, 14 electrophysiological characterization of these newly identified variants is crucial not only for accurate diagnosis but also for clinical management of patients with inherited arrhythmogenic diseases. Thus, in such conditions, clinical genome and exome sequencing, even in conjunction with powerful bioinformatics, could therefore benefit from having a platform for evaluating the functional impact of candidate variants in the physiological context of human cardiomyocytes.
In the current study, WES revealed a mutation, Gly52Val, in KCNJ2, which encodes for Kir2.1, the main gene involved in ATS; a diagnosis that would be consistent with the patient's presentation and clinical history. Furthermore, cosegregation of the Gly52Val with the disease was confirmed by genetic testing in the proband's 2 living children (1 with and 1 without ATS phenotype). Moreover, this variant was recently reported in an independent screen of 15 subjects with ATS; however, no functional studies to confirm pathogenicity was performed.
16
Figure 3. Characterization of human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) through gene expression profiling. A heat map representation of the mean expression of profiles of differentiation markers in samples of cardiac fibroblasts, hiPS, hiPS-CMs (7 and 14 d), heart tissue, and skeletal muscle tissue is shown. Genes are listed on the left vertical axis, and sample types (n=3) are listed in the horizontal axis. The heatmap shows the expression profiles of 5 different categories of genes: stem cells markers, maturation markers, cardiomyocytes makers, known long-QT (LQT) genes, and other ion channels. Expression levels are expressed as log2 expression intensity. hiPS-CMs for the Study of Novel Long-QT Variants By overexpressing Kir2.1-G52 or Kir2.1-52V in HEK cells, we have demonstrated that Kir2.1-52V expression causes dominant-negative trafficking defects and blocks the export of the channel from the Golgi to the plasma membrane which correlates with the lack of I K1 current in cells expressing Kir2.1-52V.
Although HEK cells constitute a commonly used model for characterizing the biophysical properties of ion channel mutations, their use to assess the physiological impact of mutations in ion channels and electrophysiology is limited. Although hiPS-CMs have a somewhat immature phenotype as compared with adult cardiomyocytes, patient-derived hiPS-CMs have previously been used to evaluate variant pathogenicity in LQTS1, 5, 17 LQTS2, 18, 19 LQTS3, 8, 20 and LQTS8. 21 The fact that any given patient will possess dozens of other nonsynonymous coding variants in addition to their LQTS-causing mutation can complicate the interpretation of functional studies using patient-derived hiPS-CMs. We, therefore, evaluated an alternative approach using an isogenic ready-to-use hiPS-CM line combined with genetic perturbation. Our microarray analysis clearly demonstrated that beyond being well-differentiated cells that no longer express pluripotency genes, Cor.4U hiPSCMs present a transcript expression profile similar to adult heart for many channels and cardiac markers, consistent with what has previously been reported for an analogous hiPS-CM line. 22 Our electrophysiological characterization of hiPS-CMs revealed the presence of physiological I CaL and I Na , as well as the presence of the channels predominantly mediating these currents, Cav1.2 and Nav1.5, consistent with what has been seen for other hiPS-CMs. [22] [23] [24] [25] [26] In the current study, despite an increase in KCNJ2 expression between 7 and 14 days detected by our microarray analysis, no I K1 current was detected in our hiPS-CM model. This is not unexpected considering the immature phenotype of the hiPS-CM. One of the major electrophysiological changes in normal cardiomyocyte development is the increase in I K1 current associated with the reduction of the funny current (I f ). 27 It has been previously reported that KCNJ2 expression in hiPSCMs only reached levels comparable with human myocardium at day 80 of differentiation. 26 Because our experiments were conducted between 14 and 21 days post-thaw (<60 days since cardiac differentiation), we can consider that they are still in a maturation process. Because it was previously suggested that electric stimulation could favor the maturation of hiPS-CM to more accurately represent the adult human electrophysiology, 25 cells were paced for 14 days from day 7 post-thaw to induce I K1 . After pacing, Kir2.1 was detected at the plasma membrane, and this was associated with the presence of a typical cardiac inwardly rectifying I K1 current and physiological RMP.
Given that our characterization suggested that the hiPS-CMs could potentially be a good model for functionally screening candidate causal variants, we chose to examine the KCNJ2-Gly52Val variant in this system. We first showed that hiPS-CMs recapitulate the results obtained in HEK cells. Specifically, transfection of hiPS-CMs with Kir2.1-G52 resulted in a functional Kir2.1 channel and cardiac I K1 , as well as decreasing the RMP, whereas transfection of hiPS-CMs with the Kir2.1-52V had no effect. In addition, immunohistochemistry analyses revealed that Kir-52V blocks Golgi export to plasma membrane. Kir2.1 is the major subtype of inward rectifiers expressed in the heart and coassembly of Kir2.1 homotetramers and potentially some Kir2.1-Kir2.x heterotetramers, generate I K1 . 28 It has been previously shown that highly-conserved basic amino acids in the cytoplasmic N-terminus domain of Kir2.1 (Kir2.1Δ44-76) are required for Golgi export to the cell surface. 29 It was suggested that positively charged Arg-44 and Arg-46 play a role in regulating post-Golgi export of Kir2.1. We show here that other residues are also important for Kir2.1 surface trafficking. I K1 plays a major role in the late phase of cardiac AP repolarization but also has a critical role in resting membrane stabilization, as well as regulating cardiac excitability. 30 Previous studies in animal models have demonstrated that AP is prolonged when Kir2.1 is knocked down or expressed in its dominant-negative form. 31, 32 Consequently, as we report here and as previously concluded by other groups, the depolarized RMP of hiPS-CMs makes it impossible to obtain physiologically relevant AP because at depolarized potentials, the availability of major voltage-dependent ion channels is dramatically reduced. 6, 8, 20 Accordingly, we show that electric pacing favors the development of an I K1 current and allows for successful AP triggering in >75% of the cells. These effects were completely abolished by Kir2.1-52V. Compared with the control paced group, in mutant-transfected paced cells that were able to generate AP, triggering rate was reduced, AP was dramatically prolonged, and presence of early afterdepolarizations or spontaneous depolarizations, consistent with ectopic activity and arrhythmias, were noted. Although Kir2.1-52V overexpression and chronic depolarization could potentially alter macroscopic currents 33 through a reciprocal modulation of channel expression and function, 34 our immunofluorescence studies in hiPSCMs did not detect any effect on cellular localization of Nav1.5 and Cav1.2 (data not shown), suggesting that Kir2.1-52V had no major impact on other channels than directly on Kir2.1.
ATS has only been previously studied in hiPS-CMs using simulation of a dominant-negative loss-of-function mutation through dynamic clamp. 35 Although the electrophysiological phenotype in the hiPS-CMs appeared to be slightly different from the proband, our results highly support the causality of Kir2.1-52V in ATS clinical manifestations. Such phenotypic difference is to be expected considering that overexpression of Kir2.1-52V in hiPS-CMs can exaggerate the phenotype compared with the heterozygous patient. Our study stresses the importance of early identification of potential causal variants and functional confirmation of their pathogenicity to avoid atrisk situations. Indeed, in light of AP prolongation we noted in Kir2.1-52V-expressing cells, administration of amiodarone, an antiarrhythmic agent known to prolong repolarization, would have been avoided.
In our study, we directly documented the causal relationship of the KCNJ2 variant Kir2.1-52V with ATS, without the potentially confounding effect of other nonsynonymous coding variants present in the patient. Recently, Vaidyanathan et al 36 have shown that I K1 -enhanced hiPS-CMs is a good model to study arrhythmic syndromes. However, considering the important variability in Kir2.1 current density caused by Kir2.1 adenoviral expression, characterization of ATS-causing variants would be difficult using that model. In addition, Tse et al 37 have also used a similar approach to describe the dilated cardiomyopathy phenotype caused by a novel mutation in desmin using viral transfection of hiPS-CMs. However, rather than confirming the molecular mechanism alone, here we thoroughly report its impact on physiological parameters, which could not have been studied using noncardiac cells. We thus demonstrate that commercially available hiPS-CMs represent a powerful tool for the screening of novel variants potentially involved in genetic cardiac diseases, such as LQTS. The explosion of novel genome editing techniques (e.g. Clustered Regularly Interspaced Short Palindromic Repeats-based approaches) will further develop the potential of hiPS-CM models as a 
